Creating a 3D model of brain tumors to improve treatment
Official title: A Bioprinted Volumetric Model of Vascularized Glioblastoma
Funded at Brigham and Women's Hospital · NIH-10929523 · Data updated 2026-11-12
This study is creating a 3D model of glioblastoma, a tough type of brain cancer, to help researchers see how the cancer cells grow and respond to treatments, which could lead to better ways to fight the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $405,493 |
| NIH project number | 5R01CA282451-02 |
| Project ID | NIH-10929523 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of brain tumors or those not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on developing a three-dimensional (3D) model of glioblastoma, a type of aggressive brain cancer, using advanced light-based bioprinting technology. By replicating the complex tumor microenvironment found in patients, the researchers aim to better understand how glioblastoma cells behave and interact. This model will allow for more accurate assessments of tumor growth and response to potential treatments, paving the way for improved drug screening and therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving outcomes for patients with this challenging condition.
How similar studies have gone: Previous research has shown promise in using 3D models for studying glioblastoma, indicating that this approach could yield valuable insights.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Zhang, Y. Shrike — Brigham and Women's Hospital
- Study coordinator: Zhang, Y. Shrike
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.